Compare Abbott India with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs AJANTA PHARMA - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA AJANTA PHARMA ABBOTT INDIA/
AJANTA PHARMA
 
P/E (TTM) x 44.7 23.5 190.2% View Chart
P/BV x 12.8 4.1 309.0% View Chart
Dividend Yield % 0.5 0.9 63.4%  

Financials

 ABBOTT INDIA   AJANTA PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
AJANTA PHARMA
Mar-19
ABBOTT INDIA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs6,1101,422 429.7%   
Low Rs3,996898 445.2%   
Sales per share (Unadj.) Rs1,552.2233.5 664.7%  
Earnings per share (Unadj.) Rs188.844.0 429.5%  
Cash flow per share (Unadj.) Rs196.452.2 376.6%  
Dividends per share (Unadj.) Rs55.009.00 611.1%  
Dividend yield (eoy) %1.10.8 140.3%  
Book value per share (Unadj.) Rs796.6255.1 312.3%  
Shares outstanding (eoy) m21.2588.02 24.1%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.35.0 65.5%   
Avg P/E ratio x26.826.4 101.5%  
P/CF ratio (eoy) x25.722.2 115.7%  
Price / Book Value ratio x6.34.5 139.5%  
Dividend payout %29.120.5 142.3%   
Avg Mkt Cap Rs m107,376102,081 105.2%   
No. of employees `0003.36.8 48.9%   
Total wages/salary Rs m3,9374,307 91.4%   
Avg. sales/employee Rs Th9,929.33,022.6 328.5%   
Avg. wages/employee Rs Th1,185.1633.4 187.1%   
Avg. net profit/employee Rs Th1,207.7569.1 212.2%   
INCOME DATA
Net Sales Rs m32,98520,554 160.5%  
Other income Rs m1,170211 555.0%   
Total revenues Rs m34,15520,765 164.5%   
Gross profit Rs m5,2455,664 92.6%  
Depreciation Rs m162721 22.5%   
Interest Rs m3812 329.3%   
Profit before tax Rs m6,2155,143 120.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2031,273 173.0%   
Profit after tax Rs m4,0123,870 103.7%  
Gross profit margin %15.927.6 57.7%  
Effective tax rate %35.424.8 143.2%   
Net profit margin %12.218.8 64.6%  
BALANCE SHEET DATA
Current assets Rs m22,65511,812 191.8%   
Current liabilities Rs m6,6813,776 176.9%   
Net working cap to sales %48.439.1 123.9%  
Current ratio x3.43.1 108.4%  
Inventory Days Days6577 83.7%  
Debtors Days Days2982 35.7%  
Net fixed assets Rs m83514,398 5.8%   
Share capital Rs m213175 121.2%   
"Free" reserves Rs m16,71522,277 75.0%   
Net worth Rs m16,92822,452 75.4%   
Long term debt Rs m07 0.0%   
Total assets Rs m24,16226,962 89.6%  
Interest coverage x163.7444.3 36.8%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.40.8 179.1%   
Return on assets %16.814.4 116.4%  
Return on equity %23.717.2 137.5%  
Return on capital %36.923.0 161.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36910,682 3.5%   
Fx outflow Rs m3,8072,102 181.1%   
Net fx Rs m-3,4388,580 -40.1%   
CASH FLOW
From Operations Rs m1,5273,748 40.7%  
From Investments Rs m-2,148-2,228 96.4%  
From Financial Activity Rs m-1,024-1,475 69.5%  
Net Cashflow Rs m-1,64645 -3,640.7%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 1.6 509.7%  
FIIs % 0.1 7.6 1.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 17.0 100.6%  
Shareholders   18,270 20,968 87.1%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  CADILA HEALTHCARE  NOVARTIS  PANACEA BIOTECH  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Sep 20, 2019 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS